MULTIPLE MYELOMA (MM)
Clinical trials for MULTIPLE MYELOMA (MM) explained in plain language.
Never miss a new study
Get alerted when new MULTIPLE MYELOMA (MM) trials appear
Sign up with your email to follow new studies for MULTIPLE MYELOMA (MM), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Novartis tests new drug combo for Tough-to-Treat blood cancer
Disease control TerminatedThis early-stage study aimed to find a safe dose of a new drug called WVT078, given alone and with another drug called WHG626, for people with advanced multiple myeloma. It involved 56 patients whose cancer had returned or stopped responding to at least two standard treatments. T…
Matched conditions: MULTIPLE MYELOMA (MM)
Phase: PHASE1 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Mar 30, 2026 14:28 UTC
-
Novartis halts early trial of promising blood cancer drug duo
Disease control TerminatedThis early-stage study aimed to find a safe dose and schedule for a new two-drug combination (VOB560 and MIK665) for patients whose non-Hodgkin lymphoma, acute myeloid leukemia, or multiple myeloma had returned or stopped responding to other treatments. The drugs were designed to…
Matched conditions: MULTIPLE MYELOMA (MM)
Phase: PHASE1 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Mar 23, 2026 15:29 UTC